Pharmafile Logo

Lucid Group starts new trend for CME in IBD education

October 1, 2015 |  

A tailored educational event in IBD

In the first of a series of tailored educational events, Leading Edge, part of the Lucid Group kicked off AIM100 in New York. The programme is designed to support doctors to identify IBD patients with a high risk of a poor outcome. Once identified, they will be able to assign the most appropriate treatment to ensure patients have a good outcome.
You can find out more at 
http://www.lucid-group.co.uk/#!Lucid-Group-starts-new-trend-for-CME-in-IBD-education/c1a03/560cf8cc0.

This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

Lucid celebrate big wins at PMEA 2015

Success for Lucid at PMEA 2015

Lucid invests in their Futures programme with a new hire

Lucid Group continues their expansion

Janus kinase inhibitors are amongst the most read abstracts at the American College of Rheumatology 2015

Rheumatologists eagerly await trial data for Janus kinase inhibitors

Making a difference to patients with IBD

Changing lives with medical education

Lucid Group showcases new KOL identification and mapping tool

Advancing Expert identification with digital new tool from Lucid Group

Lucid CEO discusses his inspiration and passion for changing patients’ lives

Changing patients' lives with innovative methodologies in medical education

Lucid Group starts new trend for CME in IBD education

A tailored educational event in IBD